TITLE

FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)

PUB. DATE
May 2010
SOURCE
MMWR: Morbidity & Mortality Weekly Report;5/28/2010, Vol. 59 Issue 20, p626
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the licensure of bivalent human papillomavirus vaccine (HPV2), Cervarix from GlaxoSmithKline for use in females in the U.S. by the Food and Drug Administration (FDA). It provides recommendations by the Advisory Committee on Immunization Practices (ACIP) for routine vaccination of females with HPV2 or HPV4. ACIP recommends such vaccination to prevent cervical cancers and precancers. The dosage and administration are the same for HPV4 and HPV2.
ACCESSION #
51310417

 

Related Articles

  • Gardasil approved for use in males – Cervarix gets OK for use in females.  // Contraceptive Technology Update;Dec2009, Vol. 30 Issue 12, p133 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) for the vaccine Gardasil for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11 and the Cervarix vaccine for the prevention of cervical precancer and cancer.

  • FDA Approves Quadrivalent HPV Vaccine for Use in Males Ages 9-26 Years. Garg, Arun; Guez, Ghislaine // Dental Implantology Update;Mar2011, Vol. 22 Issue 3, p23 

    The article reports on the approval of quadrivalent papillomavirus (HPV) vaccine for males between 9 to 26 years old by the U.S. Food and Drug Administration (FDA). It notes that the development of HPV vaccine for males was fast tracked due to the rising prevalence of HPV-associated cancers of...

  • FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP).  // MMWR: Morbidity & Mortality Weekly Report;5/28/2010, Vol. 59 Issue 20, p630 

    The article provides information on the licensure of quadrivalent human papillomavirus vaccine (HPV4), Gardasil from Merck & Co. Inc. by the U.S. Food and Drug Administration (FDA) for use in males to prevent genital warts caused by HPV 6 and HPV 11. The Advisory Committee on Immunization...

  • HPV protection in older groups may be in the eye of the beholder. Jones, Nicola // Nature Medicine;Jun2011, Vol. 17 Issue 6, p637 

    The article focuses on the efficacy of Gardasil vaccine from Merck & Co. Inc. against human papillomavirus (HPV) in older women cohort. Abby Lippman of McGill University comments on the lower impact of the vaccine in older women and says that engaging in sexual activity is associated in having...

  • Boniva.  // Formulary;May2005, Vol. 40 Issue 5, p144 

    Reports on U.S. Food and Drug Administration's approval of Boniva ibandronate 150-mg tablets, a first once-monthly therapy from Roche and Glaxosmithkline for treatment and prevention of osteoporosis. Efficacy and safety; Dosing.

  • Pipeline.  // Medical Marketing & Media;Dec2013, Vol. 48 Issue 12, p12 

    The article offers news briefs related to drug approval in the U.S. including the approval of lmbruvica of Pharmacyclics/Janssen by the Food and Drug Administration (FDA), Phase III trial's primary goal missed by darapladib of GlaxoSmithKline (GSK) and the need more test for eteplirsen.

  • GSK's Boostrix Approved as Treatment for Senior Citizens.  // Chain Drug Review;8/29/2011, Vol. 33 Issue 14, p37 

    The article reports on the approval of Boostrix for use in adults 65 and older by the U.S. Food and Drug Administration (FDA) to GlaxoSmithKline (GSK) PLC.

  • Two approvals boost melanoma arsenal.  // Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p494 

    The article reports on the approval received by GlaxoSmithKline from the U.S. Food and Drug Administration (FDA) for its first-in-class trametinib and second-in-class dabrafenib indicated for patients with BRAF-positive advanced or unresectable melanoma.

  • GSK wins FDA approval for new combination of breast cancer drug.  // PharmaWatch: Cancer;Mar2010, Vol. 9 Issue 3, p10 

    The article reports on the accelerated approval granted by the U.S. Food and Drugs to GlaxoSmithKline (GSK) for a new combination regimen using Tykerb as a first-line, all-oral treatment for women with metastatic breast cancer.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics